Comparing the current results to its competitors, Olink Holding Ab Publ reported Revenue increase in the 4 quarter 2023 by 21.18 % year on year, while most of its competitors have experienced contraction in revenues by -0.58 %, achieved in the same quarter.
Olink Holding Ab publ , slower than the average decrease reported by the company's competitors of -11.97 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -11.97 %
Olink Holding Ab Publ 's Comment on Competition and Industry Peers
The company operates in the life science tools market, competing with both established and early-stage firms that design, manufacture, and market assay products, services, and libraries of protein biomarker targets. Its principal competitors include Quanterix Corporation, Meso Scale Diagnostics LLC, Luminex Corporation, and SomaLogic Inc. The company also faces competition from established technologies such as ELISA and mass spectrometry.
June 6, 2024
Immune Biomarker Profiling: A New Frontier in Clinical Research UPPSALA, Sweden Olink Holding AB (Nasdaq: OLK) has announced the launch of its latest innovation, the Olink Target 48 Immune Surveillance panel. This state-of-the-art, multiplexed protein assay panel aims to revolutionize the monitoring and profiling of the immune system in clinical research. to Olink Target 48 The Olink Target 48 Immune Surveillance panel is meticulously designed to provide researchers with a comprehensive and detailed view of the immune system. This advanced tool enables the simultaneous measurement of multiple biomarkers, offering a nuanced understanding of the immune response and inflammation. Such a tool is indispensable...
April 2, 2024
Olink Insight, a leading innovator in precision proteomics, has recently announced the launch of a groundbreaking open-access data library. This library comprises more than 300,000 protein-disease risk associations across 106 human diseases, providing a valuable resource for researchers and scientists. The availability of this unprecedented information is poised to catalyze biomarker discovery and deepen our understanding of diseases, ultimately paving the way for more effective diagnostics and therapies.Enhancing Biomarker DiscoveryThe human proteome, which encompasses the entire complement of proteins in the body, plays a pivotal role in various biological processes and disease pathways. Unraveling the int...
Agilent Technologies Inc. operates a business model centered on delivering innovative measurement solutions across industries like life sciences, diagnostics, and chemical analysis. Their revenue primarily comes from sales of instruments, software, and consumables, supplemented by support services. The company emphasizes strong partnerships and collaborations to enhance their market presence and influence.
Bio-Rad Laboratories Inc operates as a global leader in life sciences and clinical diagnostics by focusing on the development, manufacturing, and distribution of a diverse array of products and solutions. Their business model emphasizes innovation, providing advanced tools and technologies that empower scientists and healthcare professionals to effectively analyze biological materials. By delivering high-quality solutions, Bio-Rad aims to facilitate scientific breakthroughs and enhance patient care in various healthcare settings.
Bruker Corporation operates as a manufacturer and supplier of scientific instruments and analytical solutions for a wide range of industries and research fields.
Cytek Biosciences Inc is a biotechnology company that specializes in developing advanced flow cytometry solutions. Their business model focuses on providing innovative flow cytometry instruments, reagents, and software to the life science research and clinical markets. By offering comprehensive and high-quality products, Cytek Biosciences aims to meet the needs of researchers and healthcare professionals in studying and analyzing cells for various applications.
Illumina Inc is a leading company in the genomics sector, focusing on next-generation sequencing technologies that enhance genetic analysis. Their business model encompasses a diverse range of products, including sequencing platforms, reagents, and bioinformatics solutions, which together facilitate comprehensive genomic studies for researchers. By integrating these tools, Illumina supports advancements in fields such as oncology, drug discovery, and personalized healthcare, positioning itself at the forefront of genomic innovation.
Sources:
Olink Holding Ab publ’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Olink Holding Ab publ versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
